Biomedical Innovation EnterpriseInstyllaRecentlyAnnounce,Its core productEmbraceHydrogel Embolic System (HES) has officially received approval from the U.S. Food and Drug Administration (FDA) Pre-market Approval (PMA）。This device will become the first one specifically used for embolizing peripheral arterial vascular hyperplasia tumors (HVT) liquid embolization platform provides a new solution for complex vascular diseases where traditional treatment methods are limited.

Angiogenic Tumor (HVT) Commonly found in the liver, kidneys, bones, and soft tissues, characterized by abnormal excessive vascular proliferation. These lesions not only have a poor prognosis but also often lead to surgical resection difficulties due to a high risk of bleeding.Embrace HESAchieving Precise Embolization in Interventional Radiology through the Innovative Design of a Two-Component Low-Viscosity Aqueous Precursor: Two precursors are simultaneously injected into the blood vessel via a catheter and rapidly crosslink to form a soft polyethylene glycol (PEG) Hydrogel, deeply penetrates the tumor vasculature and blocks blood flow。Compared with traditional embolic materials, this technology demonstrates superior vascular distribution uniformity and long-term occlusion effects.

This timeFDAApproval is based on a global coverage22A randomized controlled trial at a medical center, including150Example of angiogenic tumor patient.Data show,Embrace HESAchieved all pre-set safety and efficacy endpoints without any adverse events directly related to the device. The study results confirmed that the system was significantly superior to the current standard care in terms of embolization success rate, target vessel recanalization rate, and perioperative complication control.

It is worth noting that,EmbraceThe approval followed closelyInstyllaLaunched earlier this yearTemboAfter the bioabsorbable embolization system.TemboAs the first degradable embolic agent, it has been approved for peripheral vascular embolization and tumor vascular occlusion.The synergistic application of the two products marksInstyllaBuild a full-cycle solution covering acute embolization and long-term vascular management.

"Embrace HESThe approval marks the entry of the interventional radiology field into a new era of precise embolization."InstyllaChief Executive OfficerSean BoyleIndicates,"We are committed to addressing unmet clinical needs through innovative technologies, providing doctors with safer and more efficient treatment tools."According to market analysis, the global vascular interventional device market size is expected2030Will Break Through This Year200billion dollars, where the compound annual growth rate in the liquid embolic materials segment exceeds12%。